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Abstract 
National and international experts in inflammatory breast cancer (IBC) from high-volume 
centers treating IBC recently convened at the 10th Anniversary Conference of the Morgan 
Welch Inflammatory Breast Cancer Research Program at The University of Texas MD 
Anderson Cancer Center in Houston Texas. A consensus on the clinical management of 
patients with IBC was discussed, summarized, and subsequently reviewed. All participants at 
the conference (patients, advocates, researchers, trainees, and clinicians) were queried using 
the MDRing electronic survey on key management issues. A summary of the expert consensus 
and participant voting is presented. Bilateral breast and nodal evaluation, breast magnetic 
resonance imaging, positron emission tomography/computed tomography, and medical 
photographs were endorsed as optimal. Neoadjuvant systemic therapy, modified radical 
mastectomy and level I and II ipsilateral axillary node dissection, post-mastectomy 
radiotherapy, adjuvant targeted therapy and hormonal therapy as indicated, and delayed 
reconstruction were agreed-upon fundamental premises of standard non-protocol–based 
treatment for IBC. Consideration for local-regional therapy in de novo stage IV IBC was 
endorsed to provide local control whenever feasible. Variation across centers and special 
circumstances were discussed. 
Key words: inflammatory breast cancer, management, BCS, radiation, mastectomy, neoadjuvant chemotherapy. 
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Introduction 
In the past 10 years, coordinated focus on the 
treatment and biology of inflammatory breast cancer 
(IBC) has yielded significant progress in the clinical 
outcome. Incremental advances in systemic therapies, 
staging, surgery, new technology-based radiotherapy, 
treatment options for recurrence, standardized 
approach to a multidisciplinary management, and 
targeted therapy clinical trials based on IBC-specific 
data have improved outcomes over time.  
Collaboration between The University of Texas 
MD Anderson Cancer Center (MDA) clinicians and 
Texas and New Mexico state legislators led to the 
formation of a dedicated IBC clinic at MDA in 2006. 
This ushered forward coordination of an IBC World 
Consortium of national and international experts and 
led to the development of formalized IBC centers at 
several other major centers. National and 
international experts in IBC from high-volume centers 
treating IBC recently convened at the 10th 
Anniversary Conference of the Morgan Welch 
Inflammatory Breast Cancer Research Program at 
MDA. Review of the MDA experience shows that the 
5-year actuarial stage III overall survival has increased 
from 40-50% (for patients treated in the 1970s, 1980s, 
and 1990s) to 68% for patients treated since 2008, as 
reported at the conference.  
Herein, we review specific practices among 
high-volume IBC centers and practitioners, 
highlighting where there was a clear consensus and 
where experts agreed multiple approaches are 
reasonable given insufficient evidence for a single 
superior approach. For instances of significant 
dissenting views, the rationale and rebuttal were 
addressed. Overall, there was substantial consensus 
for recommendation of workup including bilateral 
breast and nodal evaluation, breast magnetic 
resonance imaging (MRI), positron emission 
tomography/computed tomography (PET/CT), and 
medical photographs. Neoadjuvant systemic therapy 
(NST), modified radical mastectomy and level I and II 
axillary nodal dissection, post-mastectomy 
radiotherapy to the chest wall and nodal basin, and 
delayed reconstruction were agreed-upon 
fundamental premises of standard 
non-protocol-based treatment for IBC. Consideration 
for local-regional therapy in de novo stage IV IBC was 
endorsed to provide local control whenever feasible.  
Participants 
Clinicians involved in the conference 
represented a broad cohort of IBC experts from 
high-volume centers. We include here a brief 
description of the programs represented.  
Because MDA is a tertiary referral center, IBC 
patient volume is higher, which led to the creation in 
2006 of the Morgan Welch Inflammatory Breast 
Cancer Research Program and Clinic, a dedicated 
program that sees over 100 new IBC cases per year. 
Similarly, the dedicated IBC program at the Susan F. 
Smith Center for Women’s Cancers at the 
Dana-Farber Cancer Institute has provided IBC care in 
the northeastern United States since its creation by Dr 
Beth Overmoyer in 2009 and currently sees 60 to 80 
patients per year. Dr Massimo Cristofanilli, at the 
conference representing the Robert H. Lurie 
Comprehensive Cancer Center of Northwestern 
University, was integral to the inauguration of the 
MDA program and international consortium and has 
practiced in clinical IBC programs in multiple 
academic centers. 
Throughout and after the conference, attendees, 
as well as other physicians who manage IBC, were 
surveyed using MDRing, a mobile and web based 
application that allows for users to answer multiple 
choice questions in real time (1-3). Through a simple 
question and answer format that included common 
clinical scenarios concerning IBC clinical 
management, practitioners were surveyed about the 
approach they use in daily practice. These various 
scenarios, as well as the answers to the survey, are 
described throughout the consensus. Work is ongoing 
to continue to identify and survey international IBC 
clinical leaders. All interested parties are welcome to 
contact the corresponding authors for further 
information.  
Staging workup in the setting of clinical IBC 
symptoms and a biopsy demonstrating 
invasive mammary carcinoma  
The panel strongly endorsed the value of upfront 
medical photography to document findings required 
for diagnosis and to inform all members of the 
multidisciplinary oncology team who may meet the 
patients only after resolution of skin findings. In some 
cases, patients may have taken these photos 
themselves if presenting after initiating systemic 
chemotherapy. Photos obtained by patients should be 
filed in the medical record.  
A consensus was not reached on the best upfront 
diagnostic tool, and most of the experts agreed that in 
patients without a diagnosis, bilateral mammogram 
followed by bilateral breast and nodal basin 
ultrasound are the standard initial imaging 
modalities, owing to the relatively low cost and good 
accessibility outside of an academic institution (4). 
Relevant mammographic findings include skin 
thickening (84-93%), trabecular thickening (62-81%), 
trabecular distortion (37%), increased breast density 
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(93%), calcifications (47-56%), and axillary 
adenopathy (24%), although mammography is the 
least sensitive method for primary breast lesion 
detection (5, 6). The utility of bilateral breast imaging 
to assess both bilateral breast cancer at presentation or 
cross lymphatic metastasis to the contralateral breast 
or nodal basin was described, owing to the prevalence 
of contralateral breast cancer in up to 5% of IBC 
patients at 2 years compared with approximately 1.1% 
at 2 years for non-IBC patients (7). Relevant 
ultrasound findings include skin thickening, a breast 
mass or diffuse abnormal non-mass hypoechoic tissue 
with posterior acoustic shadowing, hyperechoic foci 
representing calcifications, and nodal disease (5, 8, 9). 
If a primary breast lesion (mass or non-mass lesion) 
can be identified by ultrasound, then a core biopsy of 
the primary breast lesion and fine needle aspiration or 
core biopsy of suspicious axillary or 
infra/supraclavicular lymph node(s) should be 
performed (5, 10).  
Although data regarding the role of breast MRI 
and PET/CT for IBC specifically are lacking, 
retrospective evidence and the clinical utility of both 
modalities were reviewed. Breast MRI can detect a 
primary breast lesion in up to 100% of cases and the 
lesion can be targeted for core biopsy (11). MRI has 
also been described as the most sensitive study to 
diagnose multi-centric disease (12). Finally, MRI best 
demonstrates the extent of disease, including 
ipsilateral and contralateral skin involvement, 
enhancing skin lesions or diffuse thickening of the 
skin (97%), and breast and/or chest wall edema. 
Initial rapid enhancement with delayed washout or 
plateau curve is seen in most cases of IBC (97%) (11, 
13). A study comparing the vascular patterns in 57 
IBC patients with those of 54 non-IBC patients 
demonstrated a significant difference in the pattern of 
angiogenesis. More dome configuration was observed 
in IBC than in non-IBC (64% compared with 42%, p = 
0.03) and higher pre-pectoral vascular clusters 
appeared in IBC than in non-IBC (75% compared with 
41%, p = 0.001). These findings suggest that the 
inflammatory component may trigger increased 
vascularity and unique vascular characteristics in IBC 
(H.T. Le-Petross, unpublished data). 
The role of PET/CT in the staging of breast 
cancer, especially aggressive forms such as IBC, has 
not been clearly established. PET/CT can show not 
only the primary breast tumors as hyper metabolic 
lesions but also nodal involvement (90% of patients) 
and unsuspected distant metastases in up to 49% of 
IBC patients (14, 15). Retrospective data have shown 
that, unlike in the non-IBC locally advanced cancer 
setting, for patients with stage III IBC, adding 
PET/CT to staging on the basis of conventional 
imaging could detect metastases not detected by 
conventional imaging, thereby having a statistically 
significant effect on recurrence-free survival (p = 
0.014) (16). These are retrospective findings that need 
to be confirmed prospectively. Owing to the 
aggressive behavior of IBC, however, experts tend to 
recommend PET/CT as a staging workup tool; 
although a bone scan and CT studies of the chest, 
abdomen, and pelvis could serve as an alternative.  
 
Table 1: Optimal workup for inflammatory breast cancer 
Modality Rationale and caveats 
Medical photography Medical photographs and examinations prior to neoadjuvant chemotherapy are critical to visually determine the 
extent of skin involvement relative to future radiotherapy fields and surgery planning.  
Bilateral mammogram  For detection of microcalcifications and contralateral disease. Global skin thickening can be seen.  
Ultrasound For performing image-guided biopsy of a primary breast lesion and for nodal staging. 
Breast magnetic resonance imaging For detecting a primary breast lesion (mass or non-mass enhancement), skin thickening, breast and chest wall 
edema, chest wall and nodal involvement and contralateral breast assessment.  
Positron emission tomography/computed 
tomography (PET/CT)  
For detecting distant metastatic disease and assessing local-regional disease extent, aiding radiation and surgical 
planning. 
Bone scan and CT of the chest, abdomen, 
and pelvis 
Standard staging workup for metastatic bone disease if PET/CT is not performed. If PET/CT is not available, 
combined bone scan with standard CT scans (chest, abdomen, and pelvis). 
Pathology Core needle biopsy and skin punch biopsy for standard histopathologic examination to establish a diagnosis of 
invasive mammary carcinoma and for biomarker evaluation. 
 
 
Table 2: MDRing responses for inflammatory breast cancer workup 
Question Answers 
Yes No 
Magnetic resonance imaging is indicated for all patients with newly diagnosed inflammatory breast cancer 66% 34% 
Positron emission tomography/computed tomography is appropriate for all patients with newly diagnosed inflammatory breast cancer 71% 29% 
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 Finally, the importance of pre-systemic therapy 
cross-sectional imaging in cases of regional nodal 
involvement was highlighted, noting that the 
precision of radiotherapy relies on an understanding 
of the specific anatomic distribution of disease 
upfront (or prior to systemic therapy). Pre-treatment 
PET/CT imaging has also provided information on 
the extent of local disease resulting in modifications in 
post-mastectomy radiation treatment fields and 
radiation doses. Studies highlighting the role of 
PET/CT to change stage, surgery, or radiotherapy 
fields were reviewed (16-18). A few experts opined 
that in patients with classic symptoms of IBC, 
mammography does not add relevant clinical 
information. A proposed algorithm to be clinically 
validated in the future for clinical suspicion of IBC is 
breast MRI (to identify the primary breast lesion for 
ultrasound-guided biopsy and to detect skin lesions 
or skin enhancement suggesting tumor emboli in 
skin), ultrasound after MRI (to biopsy the most likely 
primary lesion detected on MRI and for locoregional 
nodal staging with possible nodal biopsy), and 
PET/CT (for local and distant disease workup). 
Pathology 
The role of pathology in the diagnosis, 
management, and clinical trial development of IBC 
was discussed. Because IBC is a clinicopathologic 
entity, pathologic confirmation of invasive breast 
carcinoma using image-guided core needle biopsy 
(CNB) of the affected breast is an essential part of 
diagnosis (19). Skin punch biopsy is recommended for 
examination of invasive carcinoma and dermal tumor 
emboli, with two 2-mm to 8-mm skin punch samples 
from the most prominent area of breast skin 
discoloration, however not mandated to make the 
diagnosis.  
Lymphovascular tumor emboli is a frequent 
feature of IBC, demonstrated in skin punch biopsy in 
up to 75% of patients, but their absence does not rule 
out the diagnosis (20).  
IBC is generally ductal in origin. However, other 
histological variants of mammary carcinoma can be 
encountered. The histologic characteristics of the 
invasive tumor do not appear to influence the 
survival in patients with IBC, thereby indicating that 
IBC is a distinct clinicopathologic entity that 
transcends histologic distinction (21). 
A hallmark of the invasive tumor and 
lymphovascular tumor emboli in IBC is the 
overexpression of E-cadherin, a calcium-dependent 
transmembrane glycoprotein responsible for cell 
adhesion. An overactive E-cadherin beta-catenin axis 
is suggested to be critical for the genesis of 
lymphovascular tumor emboli in IBC (22). IBC can 
belong to any of the currently known intrinsic 
subtypes of breast cancer. Pathologic evaluation of 
mastectomy specimens following completion of NST 
entails a detailed and extensive sampling of the breast 
parenchyma and skin, to determine the extent of 
residual tumor burden for accurate final pathologic 
staging of the patient. 
It is important to highlight the challenges of 
tissue procurement for undertaking correlative 
studies that are designed as an integral part of clinical 
trials for patients with IBC. The unique pathologic 
characteristics of the invasive tumor that are intrinsic 
to IBC, including noncontiguous areas of infiltration, 
reduced density of tumor cells, and edema of stroma 
separating the clusters of tumor cells, are features that 
pose significant problems in procuring high-quality 
pre-treatment core biopsies from patients with IBC. 
The quality of procured tissue is proportionate to the 
needle gauge used, length of the core, cellularity of 
the invasive tumor, and density of cells. The tumor 
cellularity of the procured core needle biopsy (CNB), 
is unpredictable regardless of whether they are fixed 
in formalin, snap frozen, embedded in optimal cutting 
temperature solution, or kept in RNA Later solution 
(Ambion) for designed genomic and proteomic 
analysis. The reported guidelines for collecting CNBs 
in clinical trials do not ensure collection of 
high-quality tissue (23). Our inability to assess the 
tumor cellularity of CNBs at the time of procurement 
is indeed a major limitation that can preclude 
successful completion of the correlative studies that 
are planned in the clinical trial. There is a need for 
better assessment of specimen tumor cellularity at the 
time of procurement.  
Optical imaging modalities that can allow 
visualization of the tissue at the bedside without the 
need for tissue processing are emerging. These 
modalities hold promise for immediate estimation of 
the quality of the CNB, thereby allowing optimal 
collection of tissue at the time of procurement. The 
results from a feasibility study, evaluating the use of 
confocal fluorescence microscopy for rapid evaluation 
of tumor cellularity in CNBs obtained from patients 
with IBC, needs further validation before it can be 
incorporated into routine clinical practice (24). The 
current availability of high-throughput genomic 
testing platforms enables us to obtain genomic data 
provided the required amount of nucleic acids is 
extracted from the collected tissue. The current 
practice of using single formalin-fixed and 
paraffin-embedded tissue sections for the proposed 
protein biomarkers to be estimated by 
immunohistochemistry can exhaust the tissue and 
limit the number of biomarkers that can be estimated. 
The currently available multiplexing platform for 
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evaluating multiple biomarkers is investigational and 
needs validation for standard evaluation of multiple 
biomarkers from a single tissue section. There is a 
great need for high-throughput proteomic platforms 
that will enable evaluation of multiple protein 
biomarkers from limited tissue. 
Systemic therapy 
All participants agreed that upfront primary 
systemic therapy, including chemotherapy or 
chemotherapy plus targeted therapy, is indicated in 
patients with stage III IBC. In patients with stage IV 
de novo IBC, participants also recommended primary 
systemic therapy to achieve optimal response, and 
patients should be evaluated for surgery and 
radiation therapy using a multidisciplinary approach. 
Although the impact of surgery and radiation therapy 
in terms of time to progression and overall survival 
are controversial in this setting, the morbidity of 
loco-regional progression is obvious and merits 
multidisciplinary intervention in those patients who 
have significant clinical response to systemic therapy, 
are well enough to undergo intensive local-regional 
therapy and have a life expectancy long enough to 
expect local progression to be an issue.  
Standard systemic therapy regimens used off 
protocol across institutions included multiple national 
guideline-concordant approaches, and such variation 
reflects the absence of data demonstrating one 
superior regimen for IBC. 
All experts agreed that sequential treatment with 
doxorubicin and cyclophosphamide, then a taxane 
with or without carboplatin should be administered 
prior to surgery in patients with HER2-negative 
disease.  
The backbone for primary chemotherapy is 
regimens that include an anthracycline and taxanes. 
This recommendation is mainly based on 
extrapolation of data available from prospective trials 
evaluating non-IBC patients. Some of these trials have 
included analyses specifically in IBC populations, 
with inconsistent results in terms of clinical outcome 
between IBC and non-IBC populations (25-27). It was 
suggested that the clinical response of non-IBC is not 
an appropriate surrogate for IBC. Therefore, the 
inclusion of IBC patients in clinical trials for the 
treatment of locally advanced breast cancer can dilute 
the interpretation of results and dedicated clinical 
trials investigating new strategies specifically for IBC 
are urgently needed.  
The largest study specifically analyzing IBC 
patients who received an anthracycline-based 
regimen followed by locoregional therapy reported a 
10-year overall survival rate of 33% (28), so the 
recommendation of MDA is the use of upfront 
anthracycline-based therapy. With the objective of 
raising pCR rates, Dana Farber Cancer Institute has 
incorporated a dose-dense anthracycline and taxane 
regimen for high-risk patients (25). Therefore, the 
recommendation was that patients receive taxane and 
doxorubicin and cyclophosphamide for primary IBC, 
to achieve the highest pCR rate.  
For HER2-positive disease, all institutions and 
participants agreed that dual anti-HER2–directed 
therapy with pertuzumab and trastuzumab should be 
used. In the NOAH trial, a pivotal trial that 
demonstrated the benefit of the anti-HER2 agent 
trastuzumab in the neoadjuvant setting, 20% of 
patients had IBC. A subgroup analysis in this 
population showed that trastuzumab added to 
chemotherapy increased the pCR rate to 48%, 
translating into an improvement of 5-year event-free 
survival (64% compared with 24%, hazard ratio 0.34) 
and 5-year overall survival (74% compared with 44%, 
hazard ratio 0.38) specifically in IBC patients (29). 
Data was presented supporting paclitaxel (T), 
pertuzumab (P) and trastuzumab (H) as preoperative 
systemic therapy for HER2-positive cancers 
(Overmoyer et al., San Antonio Breast Cancer 
Symposium 2017, abstract #501; manuscript in 
process). Dual anti-HER2 blockade was studied in the 
NeoSphere trial, in which 7% of patients had IBC, and 
the combination of pertuzumab and trastuzumab 
with chemotherapy raised the pCR rate to 45.8% (95% 
confidence interval 36.1-55.7) (30). Therefore, all 
attendees agreed to consider dual anti-HER2 therapy 
(pertuzumab and trastuzumab) combined with 
chemotherapy as the first option, with the objective of 
achieving superior pCR rates.  
 A non-anthracycline–containing regimen, 
consisting of a taxane, carboplatin, trastuzumab, and 
pertuzumab (TCHP) was recommended by some of 
the participants, based on the TRYPHAENA trial (in 
which 6% of patients had IBC, and carboplatin raised 
the pCR rate to 64%) (31). Because efficacy was not the 
primary objective of the TRYPHAENA trial, there was 
not enough evidence for the substitution of 
anthracyclines with carboplatin, so a consensus was 
not achieved. Most participants agreed that the 
carboplatin-containing regimen should be carefully 
selected owing to toxicity considerations. Therefore, 
participants agreed that for HER2-poisitve cancers, 
doxorubicin and cyclophosphamide (AC) x 4 
followed by TPH is the standard regimen for primary 
HER2 positive IBC to achieve the highest pCR rate. 
In a discussion of adjuvant therapy for 
HER2-positive disease, MDA and Dana-Farber 
Cancer Institute agreed that the standard 1-year 
anti-HER2 therapy should be trastuzumab and 
pertuzumab. This recommendation now based on the 
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recently published results from the APHINITY trial 
that showed a modest reduction in disease recurrence 
events (7.1% compared with 8.7%, hazard ratio 0.81; p 
= 0.045), with the addition of pertuzumab to 
taxane/trastuzumab containing regimen in the 
adjuvant setting. This effect is most detectable among 
patients with an increased risk of disease relapse (i.e., 
lymph node involvement or hormone receptor 
negativity) (32). Although this trial was not done 
specifically in the IBC patient population, the high 
relapse rate observed in IBC patients and major 
benefit observed in high-risk patients with breast 
cancer made participants lean toward recommending 
this intervention. Through the question and answer 
(MDRing) system provided during the meeting, 73% 
of experts attending the conference responded 
favorably to considering adjuvant dual 
HER2-directed therapy for 1 year.  
For estrogen receptor–positive disease, all 
participating institutions agreed that tamoxifen 
should be administered for 10 years in 
premenopausal women and aromatase inhibitors 
should be administered for 5 years in postmenopausal 
women. Based upon the SOFT trial, ovarian 
suppression is recommended for premenopausal 
women with hormone receptor positive IBC (33) due 
to the benefit in DFS, as long as quality of life is 
acceptable and long-term side effects are well 
explained to the patients. Whether to use aromatase 
inhibitors or tamoxifen with ovarian suppression as 
adjuvant endocrine therapy in premenopausal 
women was debated without consensus. 
No consensus emerged on the use of carboplatin 
for triple-negative IBC. Representatives of both MDA 
and Dana-Farber Cancer Institute agreed that 
although neoadjuvant carboplatin has been shown to 
increase pCR rates in triple-negative breast cancer (34, 
35), there is still not enough evidence supporting long 
term clinical efficacy to justify its routine use. In 
addition, the currently available trial data have 
excluded IBC patients or do not show specific results 
for this patient population. Therefore, a consensus did 
not emerge and most participants did not recommend 
adding carboplatin to taxane therapy outside of a 
clinical trial. 
In patients with residual invasive disease after 
NST, the addition of six to eight cycles of capecitabine 
to standard adjuvant therapy was discussed, on the 
basis of results of the CREATE-X study showing an 
increase in disease-free and overall survival, in 
HER2-negative breast cancer patients with known 
unfavorable outcomes (36). However, this was not 
agreed upon all experts, and the recommendation by 
some participants was to consider adding 
capecitabine to adjuvant treatment, for triple negative 
IBC patients who do not achieve a pCR.  
For stage IV disease, no consensus emerged on a 
preferred treatment regimen and all institutions 
agreed on the use of their own standard 
chemotherapy regimens for locally advanced disease. 
All participants agreed that the best-response 
chemotherapy regimen should be used, with the 
objective of reaching a window of opportunity for 
local control, taking into consideration patient 
performance status and quality of life.  
Finally, owing to the clear lack of randomized 
prospective controlled trials specifically in the IBC 
patient population, a recommendation was made to 
encourage care givers and patients to participate in 
clinical trials specifically designed for IBC patients, 
which can yield level I evidence that can support 
clinical care decisions. 
 
Table 3. Neoadjuvant and adjuvant systemic therapy regimens endorsed across centers 
Institution Neoadjuvant chemotherapy Comments Adjuvant therapy 
HER2-positive HER2-negative 
MD Anderson  AC ×4 followed by THP 
 
AC ×4 followed by 
paclitaxel weekly 
(or the opposite 
sequence) 
Anthracycline therapy upfront; no 
evidence for carboplatin in 
triple-negative disease outside of a 
clinical trial 
HER2-positive: trastuzumab ×1 year (refer to text 
for data concerning adjuvant pertuzumab); 
ER-positive: tamoxifen or LHRH/AI for 
premenopausal and AI for postmenopausal; no 
standard systemic chemotherapies 
Dana-Farber 
Cancer Institute 
 
THP weekly followed by; 
AC ×4 (either neoadjuvant 
or adjuvant)* 
Dose-dense AC 
followed by 
dose-dense 
paclitaxel  
*All patients receive AC after surgical 
treatment; for those with a poor 
response to TPH, AC is administered 
before surgery; no evidence for 
carboplatin in triple-negative disease 
outside of a clinical trial 
HER2-positive: Trasztuzumab and Pertuzumab to 
complete 12 mo therapy; ER-positive: LHRH/AI for 
premenopausal and AI for postmenopausal; 
consider adding capecitabine to adjuvant treatment 
for triple negative IBC patients who do not achieve 
a pCR 
Northwestern 
University 
Paclitaxel and trastuzumab 
weekly; AC ×4 
AC; paclitaxel   
Abbreviations: AC, doxorubicin and cyclophosphamide; THP, paclitaxel, trastuzumab, and pertuzumab; TCHP, docetaxel, carboplatin, trastuzumab, and pertuzumab; pCR, 
pathologic complete response; ER, estrogen receptor; LHRH, luteinizing hormone-releasing hormone agonists; AI, aromatase inhibitors. 
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Table 4: MDRing responses for systemic therapy in inflammatory breast cancer (IBC) 
Question Answers 
A 39-year-old premenopausal patient with ER-positive, PR-negative, and HER2-negative IBC has an 
estradiol level of 95 pg/mL after completing systemic chemotherapy and locoregional therapy. What is 
the standard adjuvant hormonal therapy? 
62% answered luteinizing hormone-releasing hormone 
agonist plus aromatase inhibitor 
38% answered tamoxifen 
A 45-year-old patient with triple-negative IBC received four cycles of dose-dense doxorubicin and 
cyclophosphamide ×4 followed by four cycles of paclitaxel and carboplatin. After surgery she has 
residual multifocal disease (largest diameter 2.5 cm) two of 16 axillary lymph nodes are positive for 
metastasis. Would you consider adjuvant systemic chemotherapy with six cycles of capecitabine? 
80% answered yes 
20% answered no 
In a patient with IBC that has progressed after systemic therapy, the best next step is… 3% answered definite radiotherapy without surgery 
3% answered immediate mastectomy 
84% answered new systemic therapy with a plan for 
mastectomy if further progression occurs and threatens 
the operable window 
10% answered preoperative radiotherapy 
Is carboplatin a standard chemotherapy component in triple-negative stage III IBC? 46% answered yes 
54% answered no 
Is comprehensive locoregional therapy, modified radical mastectomy, plus axillary lymph node 
dissection and post-mastectomy radiotherapy to the chest wall and nodal basin appropriate in patients 
with de novo stage IV IBC that is improving after chemotherapy with or without targeted therapy? 
82% answered yes 
18% answered no 
Is the combination of pertuzumab and trastuzumab for a 1 year a standard targeted therapy for stage 
III HER2+ IBC? 
54% answered yes 
46% answered no 
Abbreviations: ER, estrogen receptor; PR, progesterone receptor. 
 
 
Surgery 
There was widespread but not unanimous 
consensus that modified radical mastectomy and level 
I and II axillary node dissection with delayed 
reconstruction is the only guideline-concordant 
surgical option for IBC. A critical concern is not to 
leave disease behind; thus, achieving negative 
margins and removing involved skin are considered 
standard. Skin-sparing mastectomy and 
breast-conserving surgery (BCS) have not been 
prospectively studied in IBC patients. 
Breast-conserving therapy is largely considered 
contraindicated for patients with IBC in national 
guidelines because these patients were not included 
in randomized trials showing equivalence of breast 
conservation and radiation therapy compared to 
mastectomy. Local progression in IBC can be a serious 
problem and at worst lead to carcinoma en cuirasse 
with very extensive invasion that may be painful, 
ulcerate, bleed and become infected and is distressing 
for patients and care-givers. Even in patients with a 
high risk of competing distant metastasis, an 
expectation of improved rate of local control benefit in 
and of itself is considered by many a compelling 
reason to recommend mastectomy. Developing trials 
in early stage breast cancer are testing whether 
pathologic complete response may predict for those 
who can undergo less surgery however these have not 
been extended to include locally advanced patients. 
Indeed, the only prospective data regarding less 
surgery in complete responders with locally advanced 
breast cancer including IBC demonstrated higher local 
recurrence among those without complete response 
who had surgery than among those without surgery 
who achieved a pathologic complete response (37). 
Mastectomy is therefore recommended regardless of 
response in operable patients. Chest wall coverage 
with reconstructive techniques (i.e., latissimus dorsi 
flap) may be utilized when extensive skin resection is 
necessary given the extent of disease. A further 
practice point to emphasize here is that patients who 
experience disease progression during systemic 
therapy require particularly close monitoring with 
timely transition to surgery if progression to an 
inoperable status is imminent. Only when this 
operable window has closed is preoperative 
radiotherapy or chemoradiation offered.  
It was noted that the recent United Kingdom 
guidelines stop short of recommending mastectomy 
in all cases, on the basis of retrospective review of 
national practice that suggested outcomes were 
favorable in the subset of IBC patients who received 
BCS (38). A recent publication from the Edinburgh 
Breast Unit in the United Kingdom advocated BCS in 
selected patients with IBC, after reviewing 35 patients 
from a prospectively collected database over a 14-year 
period. Over a long follow-up period (median 80 
months), excellent results were demonstrated in 
locoregional recurrence-free survival (87.5% at 5 
years) and actuarial survival (70.3% at 5 years) (39). 
This cohort represents a selected subset of patients 
diagnosed with IBC with low disease burden. Case 
selection is likely to have a bearing on several other 
reported series where a breast conservation approach 
was used (40, 41). In large retrospective series the 
outcome after a conservative approach appears 
inferior, although again the caveats of retrospective 
studies are acknowledged (42). In sum, all authors 
agreed that classic, unequivocal IBC should be 
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managed by mastectomy irrespective of response. The 
role of breast conservation remains controversial. A 
breast conservation approach could be tested in the 
context of carefully selected and followed patients on 
prospective clinical trials. Patients considered for or 
requesting breast conservation must be counseled 
regarding the potential for uncontrolled loco-regional 
recurrence.  
Table 5. Surgical management recommendations by institution  
Institution Breast Nodes Caveat 
MD Anderson MRM Axillary dissection No BCS 
Dana-Farber Cancer Institute MRM Axillary dissection No BCS 
Northwestern University MRM Axillary dissection No BCS 
University of Michigan MRM Axillary dissection No BCS 
Egypt MRM Axillary dissection No BCS 
Senegal MRM Axillary dissection No BCS 
United Kingdom MRM Axillary dissection BCS in select 
cases 
Abbreviations: MRM, modified radical mastectomy; BCS, breast-conserving 
surgery. 
 
 
In addition, the recommendation for the use of 
sentinel lymph node dissection in patients with 
clinically node-positive disease treated with NST, 
based on the results of the American College of 
Surgeons Oncology Group Z1071 trial, should be 
given with caution in IBC patients because this patient 
population was actively excluded from the study (43, 
44). The results of a prospective clinical trial 
demonstrating failure to map in 75% of IBC patients, 
highlighting the importance of level I and II axillary 
lymph node dissection were presented (45). There 
was agreement that contralateral prophylactic 
mastectomy should be deferred to ensure that 
complications related to this non-oncologic surgery 
do not delay radiotherapy administration. 
Radiation 
All participants agreed that post-mastectomy 
radiotherapy is warranted in all cases and that targets 
include the chest wall and supraclavicular, 
infraclavicular, and internal mammary chain nodes. 
Radiation should specifically focus on any atypical 
geographic disease seen in the supraclavicular and 
neck nodes based on upfront cross sectional imaging. 
Similarly, care should be taken to review medical 
photographs to provide generous coverage of all skin 
disease. Recurrence patterns along the medial scar 
warrant coverage extension into the contralateral 
breast if needed. Although multiple approaches may 
be feasible, most experts agreed that minimal 
recommendations are chest wall boost to 60 Gy, 
targeting of all undissected upfront gross nodal 
disease, and use of bolus to obtain an adequate skin 
dose. Further escalation to 66 Gy twice per day, 
improved locoregional control for patients younger 
than 45 years who had positive margins and poor 
response to chemotherapy (46, 47). On the basis of this 
evidence, treatment in patients with a lack of response 
and who are relatively young may be further 
personalized and is standard at MDA. An 
outstanding 4-year local control rate of 95% similar to 
that for non-IBC patients, using the MDA tailored 
approach of accelerated dose escalation for high-risk 
non metastatic patients was recently published and 
presented, when a protocol of aggressive skin 
resection to negative margins, and complete axillary 
dissection, along with complete trimodal therapy, was 
utilized (48). In the setting of stage IV disease, 
radiotherapy was endorsed, using the same dose for 
local control. 
 
Table 6: MDRing responses for surgery in inflammatory breast cancer (IBC) 
Question Answers 
All of the following could diminish the likelihood of 
achieving local control in patients with IBC EXCEPT: 
20% answered breast-conserving surgery 
10% answered delaying or omitting surgery because skin biopsy remains positive after chemotherapy 
52% answered including the internal mammary and supraclavicular lymph nodes in radiation fields 
5% answered skin-sparing mastectomy 
13% answered tissue expander placed after mastectomy 
I believe there is a role for sentinel lymph node mapping 
in patients with IBC 
71% answered yes 
29% answered no 
I would consider breast conservation for IBC 13% answered yes 
87% answered no 
I would consider mastectomy with stage IV IBC 73% answered yes 
27% answered no 
I would offer contralateral prophylactic mastectomy at 
the time of the primary surgical therapy for the affected 
breast for a patient with IBC 
13% answered yes 
87% answered no 
Skin-sparing mastectomy is appropriate for IBC 16% answered yes 
84% answered no 
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Table 7. Radiotherapy management recommendations by institution  
Institution Targets Dose Boost 
MD Anderson  Chest wall, ICV, SCV, IMN 50 Gy; 51 Gy twice daily if <45 years, 
no pathologic complete response, and 
close margins 
Chest wall and involved undissected 
upfront regional nodes: 16 Gy or 15 Gy 
if twice per day 
Dana-Farber Cancer Institute Chest wall, ICV, SCV, IMN 50 Gy 10 Gy 
Abbreviations: ICV, infraclavicular; SCV, supraclavicular; IMN, internal mammary node. 
 
Table 8: MDRing responses for radiotherapy in inflammatory breast cancer (IBC) 
Question Answers 
What approaches are well described to improve local control for patients with 
IBC with an increased risk of local recurrence? 
8% answered bolus to promote brisk erythema 
23% answered dose > 60 Gy 
13% answered twice per day, accelerated regimens 
56% answered all of the above 
Which patients with IBC may benefit from radiation dose escalation or 
acceleration? 
5% answered close or positive margins 
2% answered younger than 45 years 
8% answered significant pathologic residual disease after systemic therapy 
85% answered all of the above 
 
Table 9: MDRing responses for reconstruction in inflammatory breast cancer (IBC) 
Questions Answers 
I believe it is appropriate to perform immediate reconstruction for IBC 18% answered yes 
82% answered no 
I would recommend placing tissue expanders at initial mastectomy to allow implant-based reconstruction in IBC  27% answered yes 
73% answered no  
 
 
Reconstruction 
All agreed that delayed reconstruction should be 
considered in IBC. The importance of removing 
involved skin in IBC was reiterated, highlighting the 
consensus that there is no role for tissue 
expander–based immediate reconstruction, given that 
this preserves skin in a skin-involved cancer. 
Immediate reconstruction was also noted to be 
suboptimal given the requirement for 
post-mastectomy radiotherapy and the likelihood of 
the radiotherapy leading to the detriment of the 
immediate reconstruction cosmesis, as well as the 
difficulty imposed by the reconstruction in providing 
adequate dose to the at-risk internal mammary nodes 
and deep chest wall. Data summarizing the feasibility 
of delayed autologous tissue reconstruction in heavily 
irradiated IBC patients from MD Anderson was 
presented, showing success rates greater than 95% 
(49, 50). Surgical options for lymphedema were 
reviewed, including lymphovenous bypass and 
vascularized lymph node transfer; 87% of patients 
have reported subjective improvements (51, 52). 
Conclusions 
In summary, by international expert consensus 
of the conference participants, the ideal IBC clinical 
framework includes upfront bilateral breast and 
nodal basin imaging with MRI and PET/CT when 
possible and upfront medical photographs. The 
treatment sequence is systemic chemotherapy for 
HER-2 normal and chemotherapy and dual antiHER-2 
therapy for HER-2 positive subtypes, followed by 
modified radical mastectomy that affords surgical 
resection of the skin, breast, and axillary nodes when 
maximal disease response occurs. Skin-sparing 
mastectomy, immediate reconstruction, sentinel 
lymph node biopsy, and contralateral prophylactic 
mastectomy are not indicated. Post-mastectomy 
radiotherapy to the chest wall and undissected 
draining lymphatics, including internal mammary 
chain and supraclavicular nodes and including boost 
fields to the chest wall and any involved regional 
nodes at presentation, is uniformly appropriate. 
Endocrine therapy is appropriate after 
post-mastectomy radiotherapy. Delayed 
reconstruction (6 months to 1 year) is endorsed given 
improving contemporary local control rates and 
demonstrated feasibility. Lymphedema microsurgery 
is a reasonable consideration in this time frame.  
There were areas of non-consensus that were not 
felt to be contentious. Broad variation in specific NST 
regimens highlights developing evidence in the 
non-IBC setting for the use of carboplatin in 
triple-negative breast cancer, as well as the role of 
dual HER2-neu targeting therapy, the use of 
dose-dense regimens, and timing of 
doxorubicin-containing regimens. In general, most 
participants continue to endorse the use of 
doxorubicin and taxane containing regimens. 
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Radiotherapy regimens also varied in the settings in 
which these data could be reviewed, although targets 
and approach were unified. Discussion remains about 
the use of ovarian suppression with tamoxifen or 
aromatase inhibitors in premenopausal women, and 
there was no consensus on the use of adjuvant 
systemic therapy for cases of inadequate response.  
The primary area of contentious non-consensus 
was in the use of skin-sparing surgeries such as breast 
conservation in carefully selected patients. Although 
the United Kingdom consensus statement has 
removed mastectomy as a mandatory surgery, strong 
dissention was voiced against considering breast 
conservation as an option for patients with, by 
definition, global skin–involved cancers and high 
rates of local progression. This may be an area of 
interest for trial development in motivated, 
well-informed patients.  
Finally, new discussions for future work to 
optimize the staging system were introduced. 
Epidemiology data have clearly demonstrated that 
patients without erythema who present with 
consistent IBC features such as a rapid onset of global 
breast swelling, peau d’orange, and nipple retraction 
are correctly diagnosed with IBC, and the American 
Joint Committee on Cancer staging system should 
acknowledge that explicit erythema may not be 
evident in all IBC patients.  
While non-scientific, the response rates of 
physician participants reflected the consensus of the 
experts overall. Areas of non-consensus may reflect 
misunderstanding or assertion of preference and are 
worthy of further study. 
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